Abstract
Background: Immature pluripotent cells are important targets for tissue engineering, regenerative medicine, and gene therapy. In addition to bone marrow derived stromal cells (BSCs), we and others have demonstrated that adipose tissue derived stromal cells (ASCs) contain mesenchymal stem cells. Compared to well characterized BSCs, ASCs are easy to obtain, have relatively low donor site morbidity, and are available for harvest in large numbers. It was previously demonstrated that ASCs differentiate into a variety of cell lineages both in vitro and in vivo. In this report, we studied the gene transfer efficiency of ASCs to evaluate their potential utility as a carrier for cell-based gene therapy. Hereinafter, the term |[ldquo]|adipose-derived stromal cells|[rdquo]| is abbreviated to |[ldquo]|ASCs|[rdquo]|, and |[ldquo]|bone marrow-derived stromal cells|[rdquo]| to |[ldquo]|BSCs|[rdquo]|. Both types are considered to include mesenchymal stem cells (MSCs).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
